ArticleDermatologic therapy2022

Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single-center, uncontrolled, prospective study in 36 weeks.

Xi-Bei Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.